Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Shift Hours' Impact on Fatigue and Tracking of Eye Dynamics

NCT07192380 · tracked via the Priya Life Science France tracker
Sponsor
IMADIS Technologies et Services
Phase
Not applicable
Started
2025-09-15
Last updated
2025-09-25

Condition(s) studied

Sleep DeprivationSleepinessEye-Tracking TechnologyRadiologistsTomographyElectroencephalography

Investigational drug(s) / intervention(s)

ElectroencephalogramActigraphyEye TrackingQuestionnaires

Electroencephalogram: EEG measurement to assess attentional state

Actigraphy: Evaluation of sleep-wake phases 24 hours prior to eye tracking measurement

Eye Tracking: Assessment of ocular parameters during controlled eye tracking: guided saccade task followed by analysis of chest scans to detect pulmonary embolism. Measurement of ocular saccade parameters (distance, velocity), fixation time and pupil diameter. Measurements performed twice: after a night on call and after a night of rest.

Questionnaires: Measurements of sleepiness (Karolinska Sleep Scale KSS, Epworth Sleep Scale ESS), mental fatigue (EVA Scale), insomnia (Insomnia Severity Index, ISI) and chronotype (Morningness Eveningness Questionnaire, MEQ) * Inclusion visit: MEQ * Before the first evaluation: ISI, KSS, ESS, EVA * Before the second evaluation: ISI, KSS, ESS, EVA

Study summary

The goal of this clinical trial is to learn how night shift-induced sleep debt affects oculomotor patterns, attentional state, and diagnostic performance in emergency radiologists.

The main questions it aims to answer are:

* Does sleep debt from a night shift alter oculomotor parameters, as eyes movements (speed and amplitude), fixation duration, pupil size?
* Does a night shift impact radiologists' diagnostic accuracy, attentional state, and perceived fatigue? Researchers will compare radiologists after a night shift (sleep-deprived) with the same radiologists after a night of rest (control) to see if fatigue-related changes affect both visual exploration strategies and diagnostic performance.

Participants will:

* Perform a guided saccade task assessed by eye tracking (primary endpoint),
* Read thoracic CT scans (with and without pulmonary embolism cases) to assess diagnostic performance and visual exploration patterns,
* Undergo EEG recording to measure attentional state,
* Complete self-report questionnaires on sleepiness and fatigue.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Associate radiologists at IMADIS Group * In their current position for at least one year * Working at one of the IMADIS Group on-call centers * Performing night shifts during the study period * Able to wear an actimeter watch during the study period (it may be removed during certain procedures, but must be put back on afterwards) * Having given their free and informed consent to participate in the study Non- inclusion criteria: * Leave during the study period * Pregnant women, women in labor, or breastfeeding women * Subjects wearing glasses or contact lenses Exclusion Criteria: \- Having slept more than 6 hours during the night shift

Primary outcome measure(s)

  • Comparison of slope of the relationship between maximum speed and saccade magnitude — Comparison of measurement obtained during an 8-minute guided saccade task during the two measurement phases : after a night call and after a night's rest
    Slope of the relationship between maximum saccadic speed and saccade magnitude This parameter reflects the dynamics of saccadic eye movements. It is derived from the main sequence, which describes the linear relationship between the amplitude of a saccade (in degrees of visual angle) and its maximum velocity (in degrees per second). The slope quantifies how rapidly maximum saccadic speed increases with increasing saccade magnitude. A steeper slope indicates faster oculomotor responses for larger saccades, whereas a reduced slope may reflect fatigue, reduced alertness, or impaired oculomotor function.

Trial sites (1)

FacilityCityRegionStatus
IMADIS Technologies et Services Lyon France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07192380 on ClinicalTrials.gov ↗ ← All trials in France